Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Maggs

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Diabetes|January 1, 1997
Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissueD G Maggs, R Jacob, F Rife, et al.
Diabetes, Obesity & Metabolism|June 1, 2011
Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysisB R Peskin, A V Shcheprov, K S Boye, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 14, 2005
Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targetsR Ratner, F Whitehouse, M S Fineman, et al.
Metabolism: Clinical and Experimental|April 30, 2002
The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetesM S Fineman, J E Koda, L Z Shen, et al.
The American Journal of Physiology|May 12, 1998
Effect of insulin on glycerol production in obese adolescentsC Robinson, W V Tamborlane, D G Maggs, et al.
The Journal of Clinical Investigation|July 1, 1995
Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscleD G Maggs, R Jacob, F Rife, et al.
The New England Journal of Medicine|March 27, 1998
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitusS E Inzucchi, D G Maggs, G R Spollett, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|October 23, 2004
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trialR E Ratner, R Dickey, M Fineman, et al.
Diabetes, Obesity & Metabolism|July 30, 2005
The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetesS A Amiel, S R Heller, I A Macdonald, et al.
Annals of Internal Medicine|February 7, 1998
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trialD G Maggs, T A Buchanan, C F Burant, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Diabetes|January 1, 1997
Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissueD G Maggs, R Jacob, F Rife, et al.
Diabetes, Obesity & Metabolism|June 1, 2011
Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysisB R Peskin, A V Shcheprov, K S Boye, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 14, 2005
Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targetsR Ratner, F Whitehouse, M S Fineman, et al.
Metabolism: Clinical and Experimental|April 30, 2002
The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetesM S Fineman, J E Koda, L Z Shen, et al.
The American Journal of Physiology|May 12, 1998
Effect of insulin on glycerol production in obese adolescentsC Robinson, W V Tamborlane, D G Maggs, et al.
The Journal of Clinical Investigation|July 1, 1995
Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscleD G Maggs, R Jacob, F Rife, et al.
The New England Journal of Medicine|March 27, 1998
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitusS E Inzucchi, D G Maggs, G R Spollett, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|October 23, 2004
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trialR E Ratner, R Dickey, M Fineman, et al.
Diabetes, Obesity & Metabolism|July 30, 2005
The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetesS A Amiel, S R Heller, I A Macdonald, et al.
Annals of Internal Medicine|February 7, 1998
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trialD G Maggs, T A Buchanan, C F Burant, et al.
Pageof 2